Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Connor A et al. | Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. | 2012 | Transplantation | pmid:23318306 |
Plock JA et al. | Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. | 2015 | Transplantation | pmid:26102613 |
Gurk-Turner C et al. | Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. | 2008 | Transplantation | pmid:18497682 |
Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
Taber DJ et al. | Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. | 2017 | Transplantation | pmid:28658199 |
Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
Benito N et al. | Alternariosis after liver transplantation. | 2001 | Transplantation | pmid:11740399 |
Diémé B et al. | Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. | 2014 | Transplantation | pmid:24598938 |
Hirose R et al. | Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. | 2000 | Transplantation | pmid:10670644 |
Han DH et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. | 2010 | Transplantation | pmid:20562737 |
Schäffer MR et al. | Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. | 1998 | Transplantation | pmid:9539093 |
Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
Manez R et al. | Rejection and hepatitis in liver transplants. | 1994 | Transplantation | pmid:7517080 |
Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
Demmers MW et al. | Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. | 2014 | Transplantation | pmid:24704664 |
Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
Jain A et al. | Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. | 2000 | Transplantation | pmid:11087149 |
Shibutani S et al. | Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. | 2005 | Transplantation | pmid:15849542 |
Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
Tory R et al. | Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. | 2009 | Transplantation | pmid:19584682 |
Dhar DK et al. | Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. | 1993 | Transplantation | pmid:7506456 |
Weiler N et al. | Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. | 2010 | Transplantation | pmid:21048536 |
Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
Luan FL et al. | Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. | 2002 | Transplantation | pmid:12042641 |
Hoogduijn MJ et al. | Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. | 2008 | Transplantation | pmid:19005411 |
Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
Gill JS et al. | Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. | 2010 | Transplantation | pmid:20098280 |
Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
Pascual J et al. | Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. | 2009 | Transplantation | pmid:19136902 |
Vossen M et al. | Bone quality in swine composite tissue allografts: effects of combination immunotherapy. | 2005 | Transplantation | pmid:16123723 |
Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
Akst LM et al. | Induction of tolerance in a rat model of laryngeal transplantation. | 2003 | Transplantation | pmid:14688529 |
Lauria MW et al. | Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. | 2010 | Transplantation | pmid:20061923 |
Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
Koch R et al. | Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. | 2003 | Transplantation | pmid:12973123 |
Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
Boots JM et al. | Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. | 2002 | Transplantation | pmid:12499885 |
Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
Mazariegos GV et al. | Weaning of immunosuppression in liver transplant recipients. | 1997 | Transplantation | pmid:9020325 |
Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
Nakazawa Y et al. | Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. | 1998 | Transplantation | pmid:9808496 |
de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
Shibasaki S et al. | Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. | 2013 | Transplantation | pmid:23269193 |
Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |
Yoshimura N et al. | A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). | 1996 | Transplantation | pmid:8633388 |